Evidence map›Paper›PMID 27274089›Full record

ReviewBioscience reports2016

Antireduction: an ancient strategy fit for future.

Petra Maria Becker

Abstract readReview
In one paragraph

Review in Bioscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. ROS production and signalling in chloroplasts: cornerstones and evolving concepts.The Plant journal : for cell and molecular biology · 2022
    Review
  10. The Redox architecture of physiological function.Current opinion in physiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Petra Maria BeckerIEZ-Institute for Ethnobotany and Zoopharmacognosy, Rijksstraatweg 158, 6573 DG Beek-Ubbergen, The Netherlands becker@ethnobotany.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While antioxidants are on everyone's lips, antireductants are their much less-known counterparts. Following an antioxidant's definition, an antireductant prevents the chemical reduction of another compound by undergoing reduction itself. Antireductants have been traced back as far as the origin of life, which they facilitated by removal of atmospheric dihydrogen, H2 Moreover, as electron acceptors, antireductants equipped the first metabolic pathways, enabling lithoautotrophic microbial growth. When the Earth's atmosphere became more oxidizing, certain antireductants revealed their Janus-face by acting as antioxidants. Both capacities, united in one compound, were detected in primary as well as plant secondary metabolites. Substantiated by product identification, such antireductants comprise antiradicals (e.g. carotenoids) up to diminishers of ruminal methane emission (e.g. fumarate, catechin or resveratrol). Beyond these Janus-faced, multifunctional compounds, the spectrum of antireductants extends to pure electron-attractors (e.g. atmospheric triplet oxygen, O2, for plant root and gut protection). Current and prospective fields of antireductant application range from health promotion over industrial production to environmental sustainability.

Indexed as

AnimalsAntioxidantsCatechinFumaratesHumansOxidantsOxygenResveratrolStilbenesAntioxidantsCatechinFumaratesOxidantsOxygenResveratrolStilbenesantioxidantsantiradicalsantireductantscarotenoidscatechindihydrogen toxicityelectro-biosynthesisflavonoidsfoodfumaratehealthindustrial productionmetabolismmethane mitigationmultifunctionalityredox biochemistryredox homoeostasisreductive stressresveratrol

Identifiers

PMID27274089
PMCPMC4986409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.